Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
These follow-on patents form a systematic attempt to add barriers of entry for generic competitors, with the intention of extending Novo Nordisks market monopoly for as long as possible when the main compound patent on the underlying active ingredient, semaglutide, expires
Injection site reactions are also relatively common , occurring in approximately 110% of patients
Key takeaways Wegovy is approved for chronic weight management and prevention of heart attack or stroke in people with obesity or who are overweight
Besides the already discussed actions of IGF-1 on glucose, it also has an indirect glucose-lowering effect secondary to its ability in increasing FA oxidation in muscle (will be further discussed in detail within the IGF - 1 and lipid metabolism section)
Initial treatment may involve weekly or monthly injections
US$ 28.38
US$ 24.20
US$ 24.26
US$ 28.87
US$ 24.96
